Journal: Cancer immunology research

Article Title: Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

doi: 10.1158/2326-6066.CIR-17-0343

Figure Lengend Snippet: a. TF expression on TNBC cancer cells (TF positive staining in brown, arrows); b. TF expression on the TNBC vascular endothelial cells (TF positive staining in brown, arrowheads); c. No TF expression in normal breast gland tissues with adenosis (TF negative); d. IHC staining with a mouse IgG isotype as a negative control. Original magnification: 400 × in a–c and 100 × in d. TF expression shown above was stained with a mouse monoclonal antibody (HTF1) and was independently verified with goat anti-human TF (Sekisui Diagnostics).

Article Snippet: Human TNBC cell lines MDA-MB-231 (BRCA1-wt, BRCA2-mutant), BT20 (BRCA1-wt, BRCA2-wt) and MDA-MB-468 (BRCA1-wt), non-TNBC lines MCF7/MDR and MCF7/MDR/TF (BRCA1-wt, BRCA2-mutant), murine breast cancer cells 4T1 and EMT6 were purchased from ATCC in 2001–2009 except for murine TNBC line 4T1 (kind gift from Dr. William Carson at The Ohio State University, 2013) and human non-TNBC lines MCF7 and MCF7/MDR (kind gift of Dr. Zping Lin at Yale University, 2008).

Techniques: Expressing, Staining, Immunohistochemistry, Negative Control

Journal: Cancer immunology research

Article Title: Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

doi: 10.1158/2326-6066.CIR-17-0343

Figure Lengend Snippet: a. TF expression on TMA with two cores from tumor tissues (upper row, TF positive cells stain brown) and two cores from normal tissues (bottom row, no TF expression) from the same TNBC patient (40 ×). b. TF expression on the TNBC cells (brown staining) (400 ×). c. No TF expression in normal breast tissues (400 ×). d. Immunohistochemical staining for TF expression on TNBC cells in TNBC whole tumor tissues and TMA tissues. TF expression shown above was stained with a mouse monoclonal antibody (HTF1) and was independently verified with goat anti-human TF (Sekisui Diagnostics). * The Scores for TF expression were graded as follows: negative (−), moderately positive (+), positive (++), strongly positive (+++) and very strongly positive (++++). Positive percentages included all cases graded from moderately positive through very strongly positive. ** Fisher’s exact test was used to test IHC score percentage difference between whole tumor tissues and TMA tissues, there is a significant difference with P = 0.0002474.

Article Snippet: Human TNBC cell lines MDA-MB-231 (BRCA1-wt, BRCA2-mutant), BT20 (BRCA1-wt, BRCA2-wt) and MDA-MB-468 (BRCA1-wt), non-TNBC lines MCF7/MDR and MCF7/MDR/TF (BRCA1-wt, BRCA2-mutant), murine breast cancer cells 4T1 and EMT6 were purchased from ATCC in 2001–2009 except for murine TNBC line 4T1 (kind gift from Dr. William Carson at The Ohio State University, 2013) and human non-TNBC lines MCF7 and MCF7/MDR (kind gift of Dr. Zping Lin at Yale University, 2008).

Techniques: Expressing, Staining, Immunohistochemical staining

Journal: Cancer immunology research

Article Title: Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

doi: 10.1158/2326-6066.CIR-17-0343

Figure Lengend Snippet: a. L-ICON1 binding to TNBC cancer lines (MD-MB-231 and BT20) and non-TNBC line (MCF7/MDR/TF). hIgG: Human IgG isotype control. b. L-ICON1 mediates ADCC effector assay for TNBC and non-TNBC cancer lines. a & b: P values were analyzed by ANOVA model. Representative results (mean ± SEM) from three independent experiments.

Article Snippet: Human TNBC cell lines MDA-MB-231 (BRCA1-wt, BRCA2-mutant), BT20 (BRCA1-wt, BRCA2-wt) and MDA-MB-468 (BRCA1-wt), non-TNBC lines MCF7/MDR and MCF7/MDR/TF (BRCA1-wt, BRCA2-mutant), murine breast cancer cells 4T1 and EMT6 were purchased from ATCC in 2001–2009 except for murine TNBC line 4T1 (kind gift from Dr. William Carson at The Ohio State University, 2013) and human non-TNBC lines MCF7 and MCF7/MDR (kind gift of Dr. Zping Lin at Yale University, 2008).

Techniques: Binding Assay, Control

Journal: Cancer immunology research

Article Title: Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

doi: 10.1158/2326-6066.CIR-17-0343

Figure Lengend Snippet: a. Therapeutic efficacy of L-ICON1 and ICON was compared in vivo by measuring tumor volume using calipers (n = 5 in each group). b. Therapeutic efficacy of L-ICON1 for TNBC was further verified by in vivo bioluminescence imaging (AdBlank and AdL-ICON1 were the same group of mice as shown in panel a, n = 5 in each group). Arrows in a & b indicate the dates when adenoviral vectors were intratumorally (i.t.) injected. c–d. Photos of TNBC-bearing control mice (c) and treated mice (d) before (day 0) and after treatment (Tx) (day 23). e. Tumor weights of control mice and L-ICON1-treated mice (P = 0.0017). f. Whole body weights indicate that L-ICON1 has no toxicity to host mice (P = 0.2190). Tumor weights (e) and body weights (f) were measured when mice were sacrificed on day 23. Ad: adenoviral vectors for control (AdBlank) and L-ICON1 (AdL-ICON1). Data are presented as mean ± SEM from one experiment. P values were analyzed by 2-way ANOVA (GraphPad). P values were analyzed by linear mixed model with random subject effects and unequal variances over days using t-test.

Article Snippet: Human TNBC cell lines MDA-MB-231 (BRCA1-wt, BRCA2-mutant), BT20 (BRCA1-wt, BRCA2-wt) and MDA-MB-468 (BRCA1-wt), non-TNBC lines MCF7/MDR and MCF7/MDR/TF (BRCA1-wt, BRCA2-mutant), murine breast cancer cells 4T1 and EMT6 were purchased from ATCC in 2001–2009 except for murine TNBC line 4T1 (kind gift from Dr. William Carson at The Ohio State University, 2013) and human non-TNBC lines MCF7 and MCF7/MDR (kind gift of Dr. Zping Lin at Yale University, 2008).

Techniques: Drug discovery, In Vivo, Imaging, Injection, Control

Journal: Cancer immunology research

Article Title: Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON

doi: 10.1158/2326-6066.CIR-17-0343

Figure Lengend Snippet: Tumor growth curves (a) and mouse survival curves (b) after intra-tumoral injection of AdL-ICON1 or AbBlank control vectors for murine breast cancer 4T1 in an orthotopic model in Balb/c mice (n = 5 in each group). Representative results (mean ± SEM) from two independent experiments. P values were analyzed by linear mixed model with random subject effects (a) or by Kaplan-Meier analysis (b).

Article Snippet: Human TNBC cell lines MDA-MB-231 (BRCA1-wt, BRCA2-mutant), BT20 (BRCA1-wt, BRCA2-wt) and MDA-MB-468 (BRCA1-wt), non-TNBC lines MCF7/MDR and MCF7/MDR/TF (BRCA1-wt, BRCA2-mutant), murine breast cancer cells 4T1 and EMT6 were purchased from ATCC in 2001–2009 except for murine TNBC line 4T1 (kind gift from Dr. William Carson at The Ohio State University, 2013) and human non-TNBC lines MCF7 and MCF7/MDR (kind gift of Dr. Zping Lin at Yale University, 2008).

Techniques: Injection, Control

Journal: Respiratory Research

Article Title: YAP/TAZ activation mediates PQ-induced lung fibrosis by sustaining senescent pulmonary epithelial cells

doi: 10.1186/s12931-024-02832-z

Figure Lengend Snippet: Paraquat treatment induces pulmonary cellular senescence in mice: A HE staining and Masson’s trichrome staining of representative lung sections from control and PQ group (original magnification 100×, scale bar = 400 μm), B SA-β-gal staining of parenchyma and trachea in lung tissues (original magnification 200×, scale bar = 200 μm), C representative images of immunoflourescence staining for p16 (red) and DAPI (blue) in lung sections (original magnification 200×, scale bar = 200 μm), D total lung protein was assessed for p16 and p21, with β-actin as loading control ( N = 8) by Western blotting, E relative mRNA levels of SASP markers Il6 , Il1a and Il8 compared to Actb in total lung tissues ( N = 4 for ctrl group, N = 6 for PQ group) were analyzed by qRT-PCR, F serum levels of SASP markers Il-6, Il-1α and Il-8 ( N = 8) were tested by ELISA assay. Values are shown as mean ± SEM. Data were analyzed by Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001

Article Snippet: The primary antibodies included anti-p16 Ink4a (for immunofluorescence: ab211542, 1:100, Abcam, UK; for Western blotting: for human: 10883-1, 1:1000, Proteintech, China; for mouse: sc-1661, 1:1000, Santa Cruz Technology, TX, United States), anti-p21 Cip1/Waf1 (sc-6246, 1:1000, Santa Cruz Technology), anti-β-actin (4970, 1:8000, CST, MA, United States), anti-Ki-67 (AG8471, 1:100, Beyotime, China), anti-α-SMA (19245, 1:200, CST), anti-pYAP (Ser127) (13008S, 1:1000, CST), anti-YAP (12395S, 1:1000 for Western blotting and 1:400 for immunohistochemisty, CST; 13584-1-AP, 1:200 for immunofluorescence, Proteintech), anti-pTAZ (Ser89) (59971S, 1:1000, CST), anti-TAZ (83669S, 1:1000 for Western blotting and 1:200 for immunofluorescence, CST), anti-Survivin (10508-1-ap, 1:1000, Proteintech), anti-Bcl-2 (BS1511, 1:1000, BioWorld, China), anti-Bax (50599-2-Ig, 1:1000, Proteintech), anti-Fn1 (sc-8422, 1:1000 for Western blotting, Santa Cruz Technology; ab45688, 1: 500 for immunofluorescence, Abcam), anti-AQP5 (20334-1-AP, 1:100, Proteintech), Sfptc (10774-1-AP, 1:200, Proteintech), anti-Cyk19 (GB12197, 1:500) and anti-Ctgf (23936-1-AP, 1:1000, Proteintech).

Techniques: Staining, Control, Western Blot, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

Journal: Respiratory Research

Article Title: YAP/TAZ activation mediates PQ-induced lung fibrosis by sustaining senescent pulmonary epithelial cells

doi: 10.1186/s12931-024-02832-z

Figure Lengend Snippet: Paraquat induces pulmonary epithelial cell senescence in vitro: A WST-1 analysis shows dose-dependent decreases of A549 and 16HBE cells after PQ exposure for 72 h, B ROS content in A549 cells after treated with 80 µM PQ for 72 h was analyzed with DHE staining (red) (original magnification 200×, scale bar = 200 μm), C A549 cells were stained with SA-β-gal after treated with 80 µM PQ for 24 h, 48 h and 72 h (original magnification 200×, scale bar = 200 μm), and quantification of positive cells, D A549 cells treated with 80 µM PQ for 24 h, 48 h and 72 h were harvested and assessed for p16 and p21, with β-actin as loading control by Western blotting, E relative mRNA levels of CDKN2A (p16), CDKN1A (p21), and SASP markers IL6 , IL1a and IL8 compared to ACTB in A549 cells treated with 80 µM PQ for 24 h, 48 h and 72 h were analyzed by qRT-PCR. F immunoflourescence staining of A549 cells treated with 80 µM PQ for 72 h for Ki-67 (red), p16 (red) and DAPI (blue) (original magnification 200×, scale bar = 200 μm), and quantification of positive cells. All statistical data were from three independent experiments. Values are shown as mean ± SEM. Data were analyzed by Student’s t test between 2 groups, and one-way ANOVA with the Dunnett’s correction was used for comparisons among multiple groups. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: The primary antibodies included anti-p16 Ink4a (for immunofluorescence: ab211542, 1:100, Abcam, UK; for Western blotting: for human: 10883-1, 1:1000, Proteintech, China; for mouse: sc-1661, 1:1000, Santa Cruz Technology, TX, United States), anti-p21 Cip1/Waf1 (sc-6246, 1:1000, Santa Cruz Technology), anti-β-actin (4970, 1:8000, CST, MA, United States), anti-Ki-67 (AG8471, 1:100, Beyotime, China), anti-α-SMA (19245, 1:200, CST), anti-pYAP (Ser127) (13008S, 1:1000, CST), anti-YAP (12395S, 1:1000 for Western blotting and 1:400 for immunohistochemisty, CST; 13584-1-AP, 1:200 for immunofluorescence, Proteintech), anti-pTAZ (Ser89) (59971S, 1:1000, CST), anti-TAZ (83669S, 1:1000 for Western blotting and 1:200 for immunofluorescence, CST), anti-Survivin (10508-1-ap, 1:1000, Proteintech), anti-Bcl-2 (BS1511, 1:1000, BioWorld, China), anti-Bax (50599-2-Ig, 1:1000, Proteintech), anti-Fn1 (sc-8422, 1:1000 for Western blotting, Santa Cruz Technology; ab45688, 1: 500 for immunofluorescence, Abcam), anti-AQP5 (20334-1-AP, 1:100, Proteintech), Sfptc (10774-1-AP, 1:200, Proteintech), anti-Cyk19 (GB12197, 1:500) and anti-Ctgf (23936-1-AP, 1:1000, Proteintech).

Techniques: In Vitro, Staining, Control, Western Blot, Quantitative RT-PCR

Journal: Respiratory Research

Article Title: YAP/TAZ activation mediates PQ-induced lung fibrosis by sustaining senescent pulmonary epithelial cells

doi: 10.1186/s12931-024-02832-z

Figure Lengend Snippet: Senescent lung epithelial cells promote lung fibroblast transformation via secreting SASP factors: A Schematic illustration of the establishment of senescent lung epithelial cell model. A549 and 16HBE cells were exposed to 200 µM PQ for 24 h, and then changed with fresh medium for continuous 6-day culture. Cells and supernatant (PQ-conditional medium, PQ-CM) were harvested at the 7th day; medium incubated with untreated cells for 48 h were harvested as control medium, B A549 cells were stained with SA-β-gal after exposed to 200 µM PQ for 24 h and continuously cultured for 6 days (original magnification 200×, scale bar = 200 μm), C A549 cells harvested at the 7th day were assessed for p16 and p21, with β-actin as loading control by Western blotting, D SASP markers IL-6, IL-1α and IL-8 in the supernatant were tested by ELISA assay, E immunoflourescence staining of HLF cells after 72 h incubation with A549 and 16HBE CM for Ki-67 (red), α-SMA (green) and DAPI (blue) (original magnification 200×, scale bar = 200 μm), and quantification of positive cells, F HLF cells incubated with CM for 72 h were assessed for α-SMA, with Tubulin as loading control by Western blotting. All statistical data were from three independent experiments. Values are shown as mean ± SEM. Data were analyzed by Student’s t test. * P < 0.05, ** P < 0.01, *** P < 0.005, **** P < 0.001, n.s. no statistical significance, # no statistical significance compared to blank medium group

Article Snippet: The primary antibodies included anti-p16 Ink4a (for immunofluorescence: ab211542, 1:100, Abcam, UK; for Western blotting: for human: 10883-1, 1:1000, Proteintech, China; for mouse: sc-1661, 1:1000, Santa Cruz Technology, TX, United States), anti-p21 Cip1/Waf1 (sc-6246, 1:1000, Santa Cruz Technology), anti-β-actin (4970, 1:8000, CST, MA, United States), anti-Ki-67 (AG8471, 1:100, Beyotime, China), anti-α-SMA (19245, 1:200, CST), anti-pYAP (Ser127) (13008S, 1:1000, CST), anti-YAP (12395S, 1:1000 for Western blotting and 1:400 for immunohistochemisty, CST; 13584-1-AP, 1:200 for immunofluorescence, Proteintech), anti-pTAZ (Ser89) (59971S, 1:1000, CST), anti-TAZ (83669S, 1:1000 for Western blotting and 1:200 for immunofluorescence, CST), anti-Survivin (10508-1-ap, 1:1000, Proteintech), anti-Bcl-2 (BS1511, 1:1000, BioWorld, China), anti-Bax (50599-2-Ig, 1:1000, Proteintech), anti-Fn1 (sc-8422, 1:1000 for Western blotting, Santa Cruz Technology; ab45688, 1: 500 for immunofluorescence, Abcam), anti-AQP5 (20334-1-AP, 1:100, Proteintech), Sfptc (10774-1-AP, 1:200, Proteintech), anti-Cyk19 (GB12197, 1:500) and anti-Ctgf (23936-1-AP, 1:1000, Proteintech).

Techniques: Transformation Assay, Incubation, Control, Staining, Cell Culture, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Respiratory Research

Article Title: YAP/TAZ activation mediates PQ-induced lung fibrosis by sustaining senescent pulmonary epithelial cells

doi: 10.1186/s12931-024-02832-z

Figure Lengend Snippet: Co-locolization of Yap/Taz and p16 is observed in type II alveolar epithelial cells and bronchial epithelial cells: A representative images of immunoflourescence staining for Yap or Taz (red), p16 (yellow), type II alveolar epithelial cell marker Sftpc (green) and DAPI (blue) in lung sections of PQ group and control group (original magnification 400×, scale bar = 100 μm), B representative images of immunoflourescence staining for Yap or Taz (red), p16 (yellow), bronchial epithelial cell marker Cytokeratin 19 (Cyk19, green) and DAPI (blue) in lung sections of control and PQ groups (original magnification 400×, scale bar = 100 μm)

Article Snippet: The primary antibodies included anti-p16 Ink4a (for immunofluorescence: ab211542, 1:100, Abcam, UK; for Western blotting: for human: 10883-1, 1:1000, Proteintech, China; for mouse: sc-1661, 1:1000, Santa Cruz Technology, TX, United States), anti-p21 Cip1/Waf1 (sc-6246, 1:1000, Santa Cruz Technology), anti-β-actin (4970, 1:8000, CST, MA, United States), anti-Ki-67 (AG8471, 1:100, Beyotime, China), anti-α-SMA (19245, 1:200, CST), anti-pYAP (Ser127) (13008S, 1:1000, CST), anti-YAP (12395S, 1:1000 for Western blotting and 1:400 for immunohistochemisty, CST; 13584-1-AP, 1:200 for immunofluorescence, Proteintech), anti-pTAZ (Ser89) (59971S, 1:1000, CST), anti-TAZ (83669S, 1:1000 for Western blotting and 1:200 for immunofluorescence, CST), anti-Survivin (10508-1-ap, 1:1000, Proteintech), anti-Bcl-2 (BS1511, 1:1000, BioWorld, China), anti-Bax (50599-2-Ig, 1:1000, Proteintech), anti-Fn1 (sc-8422, 1:1000 for Western blotting, Santa Cruz Technology; ab45688, 1: 500 for immunofluorescence, Abcam), anti-AQP5 (20334-1-AP, 1:100, Proteintech), Sfptc (10774-1-AP, 1:200, Proteintech), anti-Cyk19 (GB12197, 1:500) and anti-Ctgf (23936-1-AP, 1:1000, Proteintech).

Techniques: Staining, Marker, Control

Journal: Respiratory Research

Article Title: YAP/TAZ activation mediates PQ-induced lung fibrosis by sustaining senescent pulmonary epithelial cells

doi: 10.1186/s12931-024-02832-z

Figure Lengend Snippet: Yap and Taz knockdown abrogates paraquat-Induced pulmonary fibrosis in vivo: ( A ) Schematic illustration of the animal experiment. C57BL/6 mice were intratracheal infected with 5 × 10 10 PFU of AAV-Ctrl, AAV-shYap, AAV-shTaz or both AAV-shYap and AAV-shTaz, and intratracheal instillated with 0.02 mg PQ at day 21 postinfection. PBS was intratracheal instillated at day 0 and day 21 as blank control, ( B ) body weight of mice in each group, ( C ) Masson’s trichrome staining (original magnification 100×, scale bar = 400 μm) and ( D ) SA-β-gal staining (original magnification 100×, scale bar = 400 μm) of representative lung sections from each group: (a) blank control group, (b) AAV-Ctrl group, (c) AAV-shYap group, (d) AAV-shTaz group, (e) AAV-Yap + AAV-shTaz group, ( E ) total lung protein was assessed for p16, p21, Fn1, Ctgf, Bcl-2 and Bax, with β-actin as loading control by Western blotting ( N = 4 for PBS group, N = 6 for other groups). All graphs are shown as mean ± SEM. Parametric variables were calculated using two-tailed Student’s t test between 2 groups. * P < 0.05, ** P < 0.01, *** P < 0.005

Article Snippet: The primary antibodies included anti-p16 Ink4a (for immunofluorescence: ab211542, 1:100, Abcam, UK; for Western blotting: for human: 10883-1, 1:1000, Proteintech, China; for mouse: sc-1661, 1:1000, Santa Cruz Technology, TX, United States), anti-p21 Cip1/Waf1 (sc-6246, 1:1000, Santa Cruz Technology), anti-β-actin (4970, 1:8000, CST, MA, United States), anti-Ki-67 (AG8471, 1:100, Beyotime, China), anti-α-SMA (19245, 1:200, CST), anti-pYAP (Ser127) (13008S, 1:1000, CST), anti-YAP (12395S, 1:1000 for Western blotting and 1:400 for immunohistochemisty, CST; 13584-1-AP, 1:200 for immunofluorescence, Proteintech), anti-pTAZ (Ser89) (59971S, 1:1000, CST), anti-TAZ (83669S, 1:1000 for Western blotting and 1:200 for immunofluorescence, CST), anti-Survivin (10508-1-ap, 1:1000, Proteintech), anti-Bcl-2 (BS1511, 1:1000, BioWorld, China), anti-Bax (50599-2-Ig, 1:1000, Proteintech), anti-Fn1 (sc-8422, 1:1000 for Western blotting, Santa Cruz Technology; ab45688, 1: 500 for immunofluorescence, Abcam), anti-AQP5 (20334-1-AP, 1:100, Proteintech), Sfptc (10774-1-AP, 1:200, Proteintech), anti-Cyk19 (GB12197, 1:500) and anti-Ctgf (23936-1-AP, 1:1000, Proteintech).

Techniques: Knockdown, In Vivo, Infection, Control, Staining, Western Blot, Two Tailed Test

Journal: Cell Death Discovery

Article Title: MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction

doi: 10.1038/s41420-024-01908-5

Figure Lengend Snippet: The endogenous expression levels of STAT3, MCL1, BECN1, and SLC7A11 in a panel of NSCLC cell lines was detected by immunoblotting ( A ). A bar graph illustrates the fold change in MCL1 expression, as determined by immunoblotting in A , comparing ferroptosis-sensitive (FS) and -resistant (FR) cell lines ( B ). The expression of STAT3, MCL1, BECN1, and SLC7A11 in response to sorafenib treatment in H322, H1299, H520 and H460 cells was analyzed by immunoblotting ( C ). H322 and H520 cells, with or without sorafenib treatment, were subjected to co-immunoprecipitation and immunoblotting assays using specific antibodies to investigate protein interaction ( D ). ** p < 0.01.

Article Snippet: STAT3 mouse monoclonal IgG , Cell Signaling Technology , #9139.

Techniques: Expressing, Western Blot, Immunoprecipitation

Journal: Cell Death Discovery

Article Title: MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction

doi: 10.1038/s41420-024-01908-5

Figure Lengend Snippet: In ferroptosis-sensitive H322 cells, the efficiency of MCL1 ectopic expression, with or without sorafenib treatment, was assessed by immunoblotting ( A ). The impact of MCL1 ectopic expression on sorafenib-induced ferroptotic cell death was evaluated by flow cytometry after PI-staining ( B ). Additionally, the level of lipid peroxidation, both with and without sorafenib treatment, was determined using the MDA assay ( C ). In ferroptosis-resistant H520 cells, the effect of MCL1 knockdown on sorafenib-induced ferroptotic cell death was evaluated using flow cytometry after PI staining, both in the presence and absence of ferroptosis inhibitors ( D ). The results presented in a bar graph show the mean ± SD from three independent biological replicate experiments ( B – D ). The expression levels of STAT3, MCL1, and 4-HNE in H322 xenograft tumor lysates in response to sorafenib were gauged utilizing immunoblotting ( E ). *** p < 0.001; **** p < 0.0001.

Article Snippet: STAT3 mouse monoclonal IgG , Cell Signaling Technology , #9139.

Techniques: Expressing, Western Blot, Flow Cytometry, Staining, Multiple Displacement Amplification, Knockdown

Journal: Cell Death Discovery

Article Title: MCL1 inhibition: a promising approach to augment the efficacy of sorafenib in NSCLC through ferroptosis induction

doi: 10.1038/s41420-024-01908-5

Figure Lengend Snippet: Reagents, chemicals, assay kits, and antibodies used in this study.

Article Snippet: STAT3 mouse monoclonal IgG , Cell Signaling Technology , #9139.

Techniques: Saline, Plasmid Preparation, Multiple Displacement Amplification, GSH Assay